Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2007 Apr 2; 117(4): 889–901.
Published online 2007 Mar 22. doi:  10.1172/JCI30556
PMCID: PMC1821069

Interplay of IKK/NF-κB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy


Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder associated with dystrophin deficiency that results in chronic inflammation and severe skeletal muscle degeneration. In DMD mouse models and patients, we find that IκB kinase/NF-κB (IKK/NF-κB) signaling is persistently elevated in immune cells and regenerative muscle fibers. Ablation of 1 allele of the p65 subunit of NF-κB was sufficient to improve pathology in mdx mice, a model of DMD. In addition, conditional deletion of IKKβ in mdx mice elucidated that NF-κB functions in activated macrophages to promote inflammation and muscle necrosis and in skeletal muscle fibers to limit regeneration through the inhibition of muscle progenitor cells. Furthermore, specific pharmacological inhibition of IKK resulted in improved pathology and muscle function in mdx mice. Collectively, these results underscore the critical role of NF-κB in the progression of muscular dystrophy and suggest the IKK/NF-κB signaling pathway as a potential therapeutic target for DMD.


Duchenne muscular dystrophy (DMD) is the most common lethal X-linked recessive disorder, affecting 1 in 3,500 live male births (1). DMD children show early symptoms of muscle degeneration, frequently develop contractures, and lose the ability to walk between 6 and 12 years of age. With progressive disease, most patients succumb to death from respiratory failure and cardiac dysfunction in their twenties (2). The primary cause of this disease stems from mutations in the dystrophin gene, which is essential for the structural and functional integrity of muscles (3). Dystrophin interacts with several members of the dystrophin glycoprotein complex, which forms a mechanical as well as signaling link from the extracellular matrix to the cytoskeleton (4). Mutations in dystrophin result in membrane damage, allowing massive infiltration of immune cells, chronic inflammation, necrosis, and severe muscle degeneration (2). Normally, muscle cells possess the capacity to regenerate in response to injury signals. However, this ability is lost in DMD, presumably due to an exhaustion of satellite cells during ongoing degeneration and regeneration cycles (1). Although dystrophin mutations represent the primary cause of DMD, it is the secondary processes involving persistent inflammation and impaired regeneration that likely exacerbate disease progression.

The microenvironment of dystrophic muscles consists of elevated numbers of inflammatory cells that act as a complex interface for cytokine signaling (5, 6). In particular, TNF-α levels are upregulated in dystrophic muscles from animal models and DMD patients (7, 8). Among its pleiotropic effects, TNF-α acts as a potent inducer of the inflammatory response transcription factor NF-κB (9, 10). In mammalian cells, NF-κB consists of 5 members, RelA (p65), RelB, c-Rel, p50, and p52, of which p50/p65 is the most prototypical NF-κB complex found in cells. In inactive conditions, NF-κB is mostly retained in the cytoplasm through binding of the inhibitor protein IκB. NF-κB activation is tightly regulated by the IκB kinase (IKK) complex composed of catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ/NEMO (11). Classical stimulatory signals such as proinflammatory cytokines result in IKKβ-mediated site-specific phosphorylation and subsequent degradation of IκB by the 26S proteasome. Loss of IκB allows nuclear NF-κB accumulation and subsequent transcription of diverse genes encoding growth factors, cytokines, chemokines, antiapoptotic proteins, and cell adhesion molecules (12). In addition to this classical activation mechanism by IκB degradation, posttranslational modifications of p65 by phosphorylation, acetylation, and ubiquitination have been shown to modulate the transactivation potential of NF-κB. Therefore, NF-κB serves as a pivotal transcription factor with multiple levels of regulation that mediates a host of biological functions (9). Furthermore, chronic activation of NF-κB is frequently associated with pathophysiological states of cancer, rheumatoid arthritis, sepsis, and asthma (9, 13).

Evidence of perturbation of NF-κB signaling also exists in conditions of muscle atrophy (14, 15) and in dystrophies such as limb-girdle muscular dystrophy (LGMD) and DMD (16, 17). While NF-κB cell survival function is repressed in LGMD, NF-κB signaling is instead persistently activated in dystrophinopathies. However, relatively little is known about the mechanisms of action or regulation of NF-κB signaling in these muscular dystrophies. Moreover, the nature and origin of NF-κB activity in DMD patients has also not been resolved. In this study, we use genetic analysis of dystrophin-deficient mice to elucidate the dual contribution of IKK/NF-κB signaling originating in immune cells and that originating in skeletal muscle fibers in promoting dystrophic pathology. Furthermore, we show that inflammation is decreased and regeneration enhanced following selective pharmacological inhibition of IKK, implicating IKK/NF-κB as a suitable therapeutic target in DMD.


NF-κB is activated in immune cells and myofibers of dystrophic muscles.

In order to gain insight into NF-κB regulation in muscular dystrophy, we performed EMSA analysis on dystrophic muscles from mdx mice, a widely used mouse model of DMD (3, 4). In line with previous findings (18), NF-κB DNA binding activity was found to be significantly higher in diaphragm muscles from mdx mice compared with C57BL/10 controls (Figure (Figure1A),1A), but importantly, a similar profile was also observed in tibialis anterior (TA) and gastrocnemius muscles (Figure (Figure1B1B and Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI30556DS1). Since diaphragm represents the most affected mdx muscle (1), these results suggested that NF-κB activity positively correlated with degeneration but did not discriminate between the degree of muscle loss in different muscle groups. Supershift EMSAs revealed the binding contribution of both p50 and p65 subunits of NF-κB (Figure (Figure1B),1B), but in contrast to past findings (18) we found that this activity derived mainly from p50 and less from p65. In addition, little to no binding occurred as a result of contributions of the subunits c-Rel, RelB, p52, or Bcl-3 (data not shown). Furthermore, NF-κB activity correlated strongly with disease severity, since considerably higher NF-κB binding was associated with muscles from utrophin-dystrophin double KO (DKO) mice (19), which, compared with mdx mice, more closely recapitulate the clinical signs and early lethality of DMD patients (Figure (Figure1C).1C).

Figure 1
NF-κB activity in dystrophic muscle is localized to both muscle and immune cells.

Consistent with NF-κB binding, IKK activity as determined by Western blotting and GST-IκBα phosphorylation was also considerably higher in mdx muscles (Figure (Figure1D).1D). However, unlike classical NF-κB activation, endogenous IκBα phosphorylation and degradation were not associated with this dystrophic phenotype, a finding that was further confirmed using sucrose density–purified cytosolic fractions (Figure (Figure1D1D and data not shown). Nevertheless, we were able to clearly detect the endogenous phosphorylated form of p65 at serine residue 536 (p-p65), and kinase assays supported that p65 at serine 536 is a competent substrate for IKK phosphorylation in mdx muscles. These findings are in line with the recent notion that p65 activation by IKKβ may occur independently of classical IκB degradation (20). Further immunohistochemical analysis of mdx muscles revealed increases in the phosphorylated (Figure (Figure1E)1E) but not total form of p65 (Supplemental Figure 1B). Phosphorylated p65 was localized predominantly in immune cells and regenerating muscle fibers (see arrowheads in Figure Figure1E),1E), as confirmed by costaining with either the activated macrophage cell surface marker CD68 or the muscle regenerative marker embryonic myosin heavy chain (E-MyHC) (Figure (Figure1F1F and Supplemental Figure 1C). A similar pattern of p-p65 was also observed in muscles from DMD patients (Figure (Figure1G),1G), indicating that NF-κB signaling is also activated in clinical muscular dystrophy resembling the animal models. To assess the specificity of NF-κB activity in DMD, comparisons were made with other transcription factors and signaling proteins in mdx and DKO muscles. Although expression of Elk1 was increased, no changes were seen with Oct-1, Ets-2, p38, Ras, Raf, MEK1, SOS, and p90Rsk (Figure (Figure11 and Supplemental Figure 1, D and E), demonstrating that IKK/NF-κB is likely to represent a selective set of signaling factors regulated in dystrophic muscle.

To determine whether increases in NF-κB DNA binding and phosphorylation translated to transcriptional activity, we utilized transgenic NF-κB–luciferase reporter mice (21) (3xκB-Luc-Tg mice) that were crossed into an mdx background. Results showed that luciferase activity significantly increased only in dystrophic muscles and not in unaffected spleen, liver, or kidney (Figure (Figure2A2A and data not shown). Immunohistochemical analysis with luciferase also supported the results shown above indicating that NF-κB activity derived from both regenerating fibers and immune cells (Figure (Figure2B).2B). Interestingly, in using reporter mice, we discovered that WT neonates contained a relatively high level of skeletal muscle–specific NF-κB activity that diminished over the following weeks of postnatal development, a finding that was confirmed by classical EMSA analysis (Figure (Figure2C).2C). In mdx muscles, NF-κB activity also appeared to diminish within the first few weeks but subsequently became reactivated and persisted over time. We suspect that this maintenance in activity derives from proinflammatory or cellular damage–associated factors that begin to accumulate at around the time when levels of NF-κB in unaffected muscles would normally begin to decline. These in vivo results also indicated that the inherent loss of dystrophin itself is not sufficient to activate NF-κB. To further examine this point, we determined NF-κB determined using primary myotube cultures. Results showed that basal and TNF-induced NF-κB transcriptional activities were similar in myotubes isolated from WT and mdx 3xκB-Luc-Tg reporter mice (Figure (Figure2D),2D), as were NF-κB DNA binding activities of control, mdx, or DKO myotubes (data not shown). This argues that regulation of IKK/NF-κB signaling in dystrophic muscle occurs secondarily to the loss of dystrophin expression.

Figure 2
NF-κB activity is deregulated during postnatal development of mdx mice.

Heterozygous deletion of the p65 subunit improves dystrophic pathology.

In order to define the role of NF-κB in the dystrophic process, we used mice deficient in p65 or p50 subunits (22, 23). Since homozygous deletion of p65 results in embryonic lethality that can be rescued with further ablation of TNFa (24), triple p65, TNF-α, and dystrophin KOs were generated by crossing p65+/–TNFa–/– mice with mdx animals. Consistent with previous reports (25), we found that deletion of TNFa alone resulted in an exacerbated dystrophic pathology in an mdx background (data not shown), thereby limiting the ability to examine dystrophic muscle in the complete absence of this NF-κB subunit. Due to this limitation, p65 heterozygous mice crossed into an mdx background were instead used and compared with mdx p65 WT littermates. Histological analysis showed that muscle pathology was notably improved in mdx;p65+/– but not mdx;p50+/– mice (Figure (Figure3A).3A). Examination of mdx;p50+/– muscles revealed a predicted reduction in p50 DNA binding, and interestingly, compensatory binding of p50 occurred in muscles lacking p65 (Supplemental Figure 2A). Therefore, although p50 DNA binding activity in our hands was found to predominate NF-κB complexes in mdx muscles, this activity does not appear to influence disease, suggesting that dystrophic pathology is selectively regulated by p65.

Figure 3
Heterozygous deletion of p65 rescues mdx pathology.

We next sought to determine the mechanisms by which p65 mediates its action on dystrophic muscles. Since macrophages represent a major compartment of immune cells in dystrophinopathies (6, 26), muscles were stained with the F4/80 macrophage marker. Immunohistochemical analysis showed a marked reduction in macrophage infiltrates in the necrotic phase in mdx;p65+/– mice compared with mdx;p65+/+ littermates (Figure (Figure3B),3B), which was consistent with the associated 90% and 86% mean reduction (P < 0.01) in additional macrophage markers, lysozyme and CD68, respectively (Figure (Figure3C).3C). Decreased macrophage invasion in mdx;p65+/– mice also correlated with a 65% (P = 0.002) reduction in necrosis as determined by quantification of IgG positive–stained fibers (Figure (Figure3D),3D), while similar decreases in macrophage infiltration or necrosis were not observed in mdx;p50+/– mice (Supplemental Figure 2, B and C, and data not shown). Another hallmark of mdx muscle degeneration is the calcification deposits resulting from abnormal calcium influx or intracellular release (1). Similar to the decrease in inflammation, mdx;p65+/– mice exhibited an 88% reduction (P = 0.008) in calcification compared with mdx;p65+/+ littermates (Figure (Figure3E).3E). However, we were unable to detect reexpression of dystrophin-associated complex proteins (Supplemental Figure 2D), which shows that blocking p65 activity is not sufficient to restore the primary dystrophin deficiency present in these muscle fibers.

In response to the ongoing phases of degeneration in dystrophic muscles, cycles of regeneration attempt to compensate for the loss of muscle mass. However, this process soon ceases in DMD patients due to exhausted regenerative potential resulting from premature senescence of satellite cells and accelerated attrition in telomeres (1). Interestingly, we observed by both H&E and E-MyHC analysis that mdx;p65+/– muscles contained higher numbers of regenerating fibers compared with mdx;p65+/+ mice (Figure (Figure4A).4A). Scoring for E-MyHC–positive stained fibers revealed a mean increase of 43% in mdx;p65+/– muscles (721.2 ± 90.2) over that of muscles from mdx;p65+/+ mice (409.2 ± 77.8; P = 0.0008) (Figure (Figure4B). 4B). In addition, the percentage of centrally located nuclei (CLN) was also found to be significantly higher in mdx;p65+/– (30.05 ± 1.02) than mdx;p65+/+muscles (21.89 ± 1.68; P = 0.0002) (Figure (Figure4C).4C). To further examine NF-κB regulation of injury-induced secondary myogenesis, we utilized the well-established cardiotoxin regeneration model (27). Consistent with mdx analysis, muscle sections from p65+/– mice 6 days after cardiotoxin injection showed reduced inflammation that was associated with a significant increase in E-MyHC–positive fibers (P = 0.0002) (Figure (Figure4,4, D and E).

Figure 4
Heterozygous deletion of p65 promotes regenerative myogenesis in mdx mice.

Myeloid deletion of IKKβ reduces inflammation and necrosis in dystrophic muscles.

It is generally accepted that muscle regeneration occurs in response to injury and inflammation and that modulation of this inflammatory process would predictably decrease, rather than increase, the regeneration capacity of skeletal muscle as we had observed in mdx;p65+/– mice. One explanation for these results is that in addition to its more accepted role as a regulator of immune response, activation of NF-κB might also function in skeletal muscle as a negative regulator of myogenesis (28). In order to decipher these potential cellular functions of NF-κB in dystrophic muscle, we utilized IKKβ conditional KO mice (29). Myeloid-specific lysozyme-driven Cre transgenic mice (Lys-Cre mice) (30) were therefore crossed with mdx;IKKβF/F (flox/flox) animals, and resulting mdx;IKKβF/F;Lys-Cre offspring were obtained in expected Mendelian ratios. Due to a predominant ratio of muscle fibers to macrophages in dystrophic muscle, selective deletion of IKKβ from the immune cell compartment was undetectable by standard Western blot analysis (data not shown), but such reduction was observed by CD68/IKKβ coimmunofluorescence staining (Figure (Figure5A).5A). Consistent with the findings that IKKβ may be directly linked to p65 phosphorylation and NF-κB activity (31), reduction in IKKβ levels resulted in a decrease in p-p65 signaling in immune cells but not regenerating muscle cells (Figure (Figure5B).5B). In connection to the reduction in IKK/NF-κB signaling, muscle pathology was noticeably improved in mdx;IKKβF/F;Lys-Cre mice, which had a 51% decrease (P = 0.0019) in necrotic patches compared with mdx;IKKβF/F controls (Figure (Figure5C).5C). Nevertheless, no significant differences in CD68 expression were detected (Figure (Figure5D),5D), suggesting that IKKβ activity in macrophages is not required for the recruitment of these cells to a dystrophin-deficient muscle. However, since cytokines and chemokines contribute to a dystrophic pathology (8), we hypothesized that deletion of IKKβ in the immune cell compartment might result in a reduction in the overall inflammation burden in these diseased muscles. Indeed, by real-time PCR analysis, we observed decreases in TNF-α (58%; P = 0.011), IL-1β (66%; P = 0.002), and monocyte chemoattractant protein–1α/CC chemokine ligand 2 (MCP-1α/CCL2) (45%; P = 0.030) in mdx;IKKβF/F;Lys-Cre muscles compared with mdx;IKKβF/F controls (Figure (Figure5E).5E). Interestingly, as shown in Figure Figure5B,5B, this reduction in proinflammatory cytokines did not affect the activated state of p65 originating in muscle fibers from mdx;IKKβF/F;Lys-Cre mice, suggesting that other mediators in addition to TNF-α and IL-1β contribute to the persistent activation of NF-κB in dystrophic muscle. Moreover, quantitation analysis of E-MyHC staining revealed that there were no significant differences in the number of regenerating fibers between these groups of mice (data not shown), further suggesting that the primary role of IKKβ/NF-κB signaling in recruited macrophages is to promote the proinflammatory network leading to muscle necrosis.

Figure 5
IKKβ deletion in myeloid cells reduces inflammation.

Myofiber-specific deletion of IKKβ promotes regeneration in dystrophic muscles.

Having gained insight into the role of NF-κB signaling in the immune cell compartment of dystrophin-deficient muscle, we now turned our attention to the requirement of this signaling pathway in skeletal muscle fibers. For this analysis, mdx;IKKF/F mice were crossed with Cre knock-in mice under the regulation of the myosin light chain 1f promoter (MLC-Cre mice), whose expression has been shown to be highly restricted to skeletal muscles (32). Surprisingly, genotyping analysis from more than 100 progeny showed that MLC-Cre animals, in contrast to myeloid-depleted IKKβ mice, were not obtained in the expected Mendelian ratios, and more than 98% of the viable mdx;IKKβF/F;MLC-Cre litters were females, suggesting a sex bias in the segregation of these alleles Since expression of MLC-1f occurs early in skeletal muscle development (32, 33), it is possible that the requirement of IKKβ during embryonic development might be differentially regulated in a sex-specific manner in a dystrophic background. Based on these considerations, mdx;IKKβF/F;MLC-Cre female mice were used for our analyses and were compared with age-matched mdx;IKKβF/F female controls. Immunoblots confirmed that IKKβ was efficiently, but not completely, deleted in mdx;IKKβF/F;MLC-Cre muscles (Figure (Figure6A).6A). Nevertheless, reduction was sufficient to concomitantly decrease p-p65 specifically in regenerative fiber nuclei, without significantly affecting IκB phosphorylation or turnover (Figure (Figure6,6, B and C). In addition, histological analysis of mdx;IKKβF/F;MLC-Cre muscles revealed a noticeable increase in regeneration in muscles lacking IKK/NF-κB signaling (Figure (Figure6D),6D), which we quantitatively confirmed by E-MyHC staining (423.5 ± 91.72 E-MyHC–positive stained fibers in mdx;IKKβF/F;MLC-Cre mice compared with 182.29 ± 15.79 in mdx;IKKβF/F mice; P = 0.0008) and by scoring for centronucleated fibers (27.63% ± 3.48% in mdx;IKKβF/F;MLC-Cre mice compared with 21.72% ± 1.21% in mdx;IKKβF/F mice; P = 0.0358) (Figure (Figure6E6E and Supplemental Figure 3A). This analysis was performed at 4 weeks of age, when the regeneration phase in mdx mice begins to peak. Morphometric measurements revealed that at this time, regenerative fibers in mdx;IKKβF/F;MLC-Cre mice were smaller than those in mdx;IKKβF/F mice. However, when fiber measurements were repeated at 12 weeks of age, fibers in mdx;IKKβF/F;MLC-Cre muscles were found to be significantly larger (Figure (Figure6F),6F), suggesting that the higher regeneration capacity in mdx;IKKβF/F;MLC-Cre mice eventually culminated in more mature fiber formation. Taken together, these results support the existence of a pathway of IKKβ-mediated NF-κB regulation in skeletal muscle that functions to inhibit regeneration in muscular dystrophy.

Figure 6
IKKβ deletion in muscle cells promotes regeneration.

Muscle progenitor cells are increased in myofibers lacking IKKβ in dystrophic muscle.

Since muscle repair is integrally linked to immune regulation (6), we considered the possibility that one mechanism by which loss of IKKβ/NF-κB signaling in skeletal muscle could promote regeneration is through a concomitant reduction of immune modulators emanating from skeletal muscle tissue itself. However, histological analysis of mdx;IKKβF/F and mdx;IKKβF/F;MLC-Cre muscles revealed no overt decreases in the number of immune cells, a finding that was confirmed by CD68 analysis (Figure (Figure7A). 7A). Furthermore, while there was a reduction in TNF-α expression, no significant changes were seen in cytokine and chemokine genes IL-1β, MCP-1, RANTES, and MIP-1α (macrophage inflammatory protein 1α) (Figure (Figure7A),7A), supporting the notion that muscle regeneration due to a deletion of myofiber IKKβ/NF-κB signaling is not primarily mediated by an attenuated immune response. Increased regeneration also did not correlate directly with the degree of muscle damage, since the percentage of necrosis did not significantly differ between mdx;IKKβF/F;MLC-Cre and mdx;IKKβF/F muscles (Supplemental Figure 3B).

Figure 7
Muscle progenitor cells increase in mice lacking IKKβ.

Given that TNF-α expression was found to be lower in mdx;IKKβF/F;MLC-Cre muscles and that this cytokine has been shown to inhibit myogenesis through the activation of NF-κB and the modulation of MyoD (34), we next considered that the ability of NF-κB to repress regeneration in dystrophic muscle might be linked to its negative regulation of the myogenic program. Indeed, assessment of MyoD by immunostaining revealed a 41% (P = 0.0014) increase in mdx;IKKβF/F;MLC-Cre compared with mdx;IKKβF/F muscles, and similar results were found when MyoD levels were examined in mdx;p65+/– mice (Figure (Figure7B).7B). These data support earlier in vitro findings (34) and suggest that increases in MyoD may be a contributing factor to the enhancement of myogenesis in muscles lacking NF-κB signaling. Since expression of MyoD is represented in activated satellite cells committed to a myogenic lineage and differentiation in response to injury (27), we further speculated that NF-κB regulation of myogenesis might extend to the level of myogenic progenitors or satellite cells. By standard immunohistochemical stains, attempts to measure the satellite cell marker Pax7 were unsuccessful in determining specific nuclear reactivity, but immunoblotting detected an induction of Pax7 in mdx muscles that was further increased in fibers lacking NF-κB (Figure (Figure7C).7C). Enhancement of Pax7 in mdx;IKKβF/F;MLC-Cre muscles was substantiated when immunostaining was performed in freshly isolated satellite cells that were immediately fixed and quantitated following 2 short preplating steps to minimize fibroblast contamination (Figure (Figure7D).7D). Furthermore, satellite cultures prepared from mdx;IKKβF/F;MLC-Cre muscles also led to a 43% increase in myotube formation (P = 0.0001) (Figure (Figure7E).7E). This regulation of satellite cells was specific to the dystrophic condition, since IKKβF/F;MLC-Cre muscles on a WT background appeared indistinguishable from those of IKKβF/F or WT littermates, with no evidence of regeneration or Pax7 deregulation (Supplemental Figure 3, C and D).

Although the exact origin of satellite cells remains elusive, adult muscle–derived progenitor populations with stem cell–like properties that contribute to muscle formation during injury were recently identified (35, 36). To further assess the extent of regulation of the IKK/NF-κB signaling pathway in the satellite cell lineage during regenerative myogenesis, muscle progenitor populations from mdx;IKKβF/F;MLC-Cre mice were isolated and analyzed by flow cytometry (Figure (Figure7F).7F). Combinatorial FACS analysis with CD34 and Sca-1 surface markers showed a 39% higher proportion of CD34+Sca-1 cells in mdx;IKKβF/F;MLC-Cre mice compared with their mdx;IKKβF/F littermates. Since the CD34+Sca-1 fraction of progenitor population isolated from adult muscles was found to display myogenic activity in vitro (Supplemental Figure 3F) as well as in vivo (35, 36), it is possible that increases in this fraction detected in mdx muscles lacking NF-κB represent another source of enhanced regenerative potential. Collectively, these results indicate that chronic activation of IKK/NF-κB signaling in mdx muscle contributes to dystrophic pathology through the negative regulation of an adult skeletal muscle progenitor cell population.

Pharmacological inhibition of IKK identifies the IKK/NF-κB signaling pathway as a therapeutic target in muscular dystrophy.

Our results from biochemical and genetic analyses implicate IKK/NF-κB signaling in the pathogenesis of DMD. To examine whether this signaling pathway is a target for DMD treatment, we utilized the cell-permeable NEMO-binding domain (NBD) peptide (Figure (Figure8A),8A), which was engineered from the C terminus of IKKβ and shown to function as a specific IKK inhibitor (37). In vivo, systemic administration of NBD peptide is not toxic in mice and inhibition of NF-κB correlates with attenuation of inflammatory response in other disease models (38). Indeed, treatment of prenecrotic 6-day-old mdx mice with WT NBD peptide resulted in a significant mean decrease (80%; P = 0.034) in macrophage infiltration in muscles as compared with similar administration with a mutant version of the peptide (Figure (Figure8B). 8B). Consistent with the notion that macrophages promote inflammation-related membrane injury (6), decreased immune invasion was associated with a 77% reduction (P = 0.035) in membrane lysis with WT, but not mutant, NBD treatment (Supplemental Figure 4, A and B).

Figure 8
Pharmacological inhibition of IKK rescues the histopathology and function of dystrophic muscle.

Next we asked whether NBD therapy would prove efficacious if treatment was pursued during the postnecrotic phase in mdx mice. To this end, we began treatment from 23 days of age and continued for an additional 4 weeks. WT NBD but not mutant peptide treatment was successful in reducing NF-κB activity, as assessed by p-p65, which was again seen to be independent of IκBα turnover (Figure (Figure8,8, C and D). Consistent with phenotypes from genetic ablations of p65 and IKKβ, treatment of mdx mice with WT peptide caused a marked reduction in levels of immune infiltrates (Figure (Figure8,8, E and F, and Supplemental Figure 4C). In contrast, only mild effects were observed in mutant NBD–treated compared with untreated mdx mice. Furthermore, we addressed whether pharmacological inhibition of NF-κB could promote muscle repair. Again, as seen with the genetic models, treatment of mdx mice with WT NBD peptide increased the number of E-MyHC fibers by 47%, with a smaller, but significant, increase of 24% in centronucleated fibers (P = 0.0007) (Figure (Figure8G).8G).

A major consequence of the dystrophic process is the inability of degenerated muscles to produce a normal level of developed force in DMD patients (1), which is mimicked in diaphragm muscles from mdx mice (39). Measurements of active force developed by diaphragm muscles from mdx mice treated with WT NBD or mutant peptide were therefore performed in independent experiments in blinded fashion. Results revealed that diaphragm muscles from WT NBD–treated mice had significantly higher developed tetanic force (54.0 ± 7.8 mN/mm2; n = 31) compared with mutant peptide–treated mice (36.9 ± 4.7 mN/mm2; n = 22) (P = 0.048) (Figure (Figure8H), 8H), suggesting that restored muscle pathology and enhanced regeneration in mice treated with a specific IKK inhibitor correlated with improved muscle function. Taken together, these results elucidate that targeting the IKK/NF-κB signaling pathway could be of clinical relevance in muscular dystrophies, specifically in improving the secondary pathology that is critical to the disease progression of DMD.


The data presented here provide genetic evidence supporting the role of IKK/NF-κB in the pathogenesis of muscular dystrophy and mark this signaling pathway as a potential therapeutic target for the management of DMD. Our results are consistent with previous studies (16, 17) in describing the activation of NF-κB in dystrophic muscles; however, in contrast to the earlier studies, we find this activity to be associated with both immune cells and regenerative muscle fibers. We also show that NF-κB activity in mdx mice resists the normal downregulation seen during postnatal development in WT mice. Because this activation coincides with the initiating phases of mdx pathology, we suspect that inflammatory signals are likely to be involved in this regulation. Another distinguishing feature of our study is the presence of chronic NF-κB activity without evidence of classical IκBα phosphorylation and turnover. In fact, the data instead point to elevated IKK activity that activates p65 transcriptional activity through phosphorylation of serine 536. Although in our hands EMSAs revealed predominant p50 binding in dystrophic muscles, unlike in disuse atrophy (14, 15), genetic analysis did not support the involvement of this subunit in mdx pathology. Studies utilizing homozygous p50 mutant mice will be needed to substantiate the role of p50 in dystrophic muscles.

One of the mechanisms by which IKK/NF-κB signaling appears to contribute to dystrophy is by promoting chronic inflammation. Due to the wide range of NF-κB target genes, including cytokines and chemokines (9), we speculate that NF-κB–mediated transcription might serve as an amplification signal for persistent immune response in dystrophic muscle. In effect, the reduction in inflammatory response in mdx mice with heterozygous deletion of p65, myeloid-specific deletion of IKKβ, or treatment with NBD peptide supports such a notion. Besides immune cells, injured muscle fibers also act as sources of cytokines and chemokines involved in immune cell chemotaxis (6). However, dystrophic muscles lacking IKKβ showed levels of macrophages similar to those in control mdx mice, suggesting that IKKβ function in muscle cells is not likely to involve a chemotactic response. Nevertheless, the regulation of TNF-α detected from both IKKβ-deleted myeloid and muscle cells supports the hypothesis that the decrease in inflammation observed in p65+/– and NBD-treated mice could result from an impaired inflammatory signaling loop between muscle fibers and immune cells. It is also possible that the activation of NF-κB emanating from other immune compartments such as mast and T cells (6, 10) might contribute to the inflammatory processes in dystrophic muscles.

A second mechanism by which IKK/NF-κB signaling regulates the dystrophic process is repression of muscle regeneration. The findings in this study suggest that blocking NF-κB function either genetically or by pharmacological means promotes formation of new myofibers in response to degeneration. These results are highly consistent with recent evidence that IKK deletion in muscles in response to acute injury can also lead to increased regeneration (40). Muscle regeneration after injury represents a coordinated sequence of events involving the activation of quiescent satellite cells into myoblasts and their subsequent fusion to newly formed myotubes (27). NF-κB has been previously shown to repress the differentiation program by targeting MyoD (34) and by preventing myoblast fusion in vitro (41). Our current in vivo study is consistent with previous in vitro findings that TNF-α inhibits myogenesis through repression of MyoD (34). Importantly, the data also reveal a new mechanism by which the NF-κB signaling pathway regulates the early initiating steps of regenerative myogenesis by modulating progenitor cell number in dystrophic muscles, although exactly how NF-κB mediates this action on the progenitor population, satellite cells, or myoblasts during regeneration remains to be further explored. However, based on our results, it is tempting to speculate that NF-κB signaling from damaged myofibers could potentially limit the activation of progenitor populations and interfere with their participation in repair.

Importantly, since satellite cells are exhausted very early due to futile rounds of degeneration and regeneration cycles in muscles of DMD patients (1, 4), any pharmacological agent that blocks NF-κB and maintains or replenishes the progenitor population even partially could possibly improve muscle pathology and function. Furthermore, if NF-κB inhibition in the early stages of dystrophy can reduce the inflammation burden, this might in turn slow the initial exhaustion of the regenerative capacity in dystrophic muscles. Sustained inhibition of IKK/NF-κB signaling could in turn allow dystrophic muscles to recuperate and reinitiate muscle repair in the later phases of the disease. Since NF-κB regulation maintains a delicate balance between cell survival and apoptosis and is very important for host defense mechanisms, the specificity and duration of the NF-κB–inhibiting agent becomes highly relevant in designing effective pharmacological therapies against chronic diseases. Whereas IKKβ inhibition in macrophages is beneficial in reducing inflammation in cancer (42), IKKα loss in macrophages can actually elevate the immune response by increasing the production of proinflammatory cytokines and chemokines (43), thus underscoring the importance of specificity for IKK inhibitors. Similarly, though administration of nonspecific agents such as MG-132 (44) and, more recently, a synthetic antioxidant (45), has been shown to ameliorate the dystrophic phenotype, risks of inhibiting unwanted cellular targets can also sometimes outweigh the benefits (46). In addition, our inability to detect clear evidence of IκBα degradation in dystrophic muscles may argue against the use of general proteasome inhibitors as a therapeutic strategy for blocking classical NF-κB signaling in DMD. Hence, the implementation of a specific NF-κB inhibitor such as the NBD peptide might provide maximal therapeutic benefit with minimal side effects (47). Although long-term inhibition of NF-κB is associated with a vulnerability to bacterial infections and mounting immune responses (48), it is noteworthy that the NBD peptide has not been found to block basal NF-κB activity (37) and, as seen in this and previously described studies, does not exhibit overt signs of toxicity (38, 47). Together, the results identify the IKK/NF-κB signaling pathway as a viable target for anti-DMD therapy.



mdx (C57BL/10 ScSn DMDmdx), NF-κB1+/–, TNFa–/–, and Lys-Cre mice were purchased from The Jackson Laboratory and NF-κB reporter mice from Xenogen. All genotypes were determined by PCR analysis from tail DNA. Mice were housed in the animal facilities of The Ohio State University Comprehensive Cancer Center under conventional conditions with constant temperature and humidity and fed a standard diet. Animal experimentation was approved by The Ohio State University Animal Care and Use Committee. For cardiotoxin experiments, 100 μl of 10 μM cardiotoxin dissolved in PBS was injected into the TA of either p65+/+ or p65+/– mice. NBD peptide synthesis is described in the Supplemental material. Peptide injections were performed using 2 regimens in independent laboratories. In one group of male mdx mice, peptides were injected intraperitoneally, beginning at 6 days of age, daily for 22 days at 10 mg/kg. In a second group, peptides were injected intraperitoneally at 200 μg per mouse, beginning at 23 days of age, once every 3 days for 27 days.


DMD muscle biopsies were obtained in accordance with the Institutional Review Boards of Columbus Children’s Research Institute after informed consent.


Frozen muscle sections were stained as previously described (49). For immunostaining, p-p65 antibodies (either unconjugated or Alexa Fluor 488 conjugated) (1:500; Cell Signaling Technology), p65 (1:5,000; Rockland), luciferase (1:1,000; Sigma-Aldrich), MyoD (1:50; Dako), F4/80 (1:500; Serotec), E-MyHC (1:50; Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, Iowa, USA), CD68 (1:500; Serotec), IKKβ (1:50; Imgenex), or MyHC (1:500, Sigma-Aldrich) were used. Immunofluorescence of cultured cells with E-MyHC (1:50) and Pax7 (1:100) (Developmental Studies Hybridoma Bank) was used. Rhodamine- and Oregon green–conjugated secondary antibodies (1:250; Molecular Probes; Invitrogen) were used for indirect immunofluorescence, and Hoescht stain (1:10,000; Sigma-Aldrich) was used for nuclear detection. For E-MyHC and centronucleation quantitation, counts were performed from a minimum of 20 randomly chosen fields, from 5–6 sections throughout the length of the muscle in 4–6 animals per group. Calcifications were identified by von Kossa and H&E staining (49), and staining of muscle sections for cytoplasmic IgG accumulation was performed as previously described (50). Fiber diameter measurements were determined as reported previously (49).

Satellite cell isolation.

Total hind limb muscles (3 mice per group) were digested with type II collagenase (Worthington Biochemical Corp.) and dispase (Roche Diagnostics) for 70 minutes, and cell suspensions were then preplated for an hour in tissue culture flasks containing supplemented DMEM media as previously described (51). Nonadherent cells were centrifuged, counted, and labeled with biotin-conjugated CD34, clone RAM 34 (eBiosciences). Negative control staining was performed with the omission of the primary antibody. Cells were then incubated with anti-biotin paramagnetic beads and selected using a MiniMACS separation system according to the manufacturer’s instructions (Miltenyi Biotec). Cells were subsequently labeled with streptavidin coupled to PE (BD Biosciences — Pharmingen) and then incubated with FITC-conjugated Sca-1 antibody (clone D7; BD Biosciences — Pharmingen) for flow cytometry analysis (FACSAria cytometer using FACSDiva software; BD Biosciences). Sorted gates were defined based on isotype controls and single stained cells, and sorted cells were differentiated as described previously (52). Satellite cells were isolated as described previously (53, 54).

Functional analysis.

Diaphragm muscles were rapidly excised and placed in ice-cold standard Krebs-Henseleit solution. Diaphragm strips (0.9 ± 0.03 mm wide; 1–4 strips per mouse) were mounted between a force transducer (KG-7; Scientific Instruments) and a micromanipulator device in the experimental setup. The muscle was allowed to stabilize at 37°C in Krebs-Henseleit solution with constant oxygenation. Following delivery of a monophasic stimulus to the muscle, the voltage was gradually increased until all motor units were activated. Subsequently, the muscle was slowly stretched to determine the optimal length. The muscle was then rested for 5 minutes before the tetanic protocol was started. Maximal tetanic contraction was assessed at 250 Hz for a 600-ms duration. In addition, to investigate a potentially different frequency response between groups, tetani were assessed by sequential stimulation at 20, 50, 80, 120, 150, 200, and 250 Hz with 2 minutes rest in between. The cross-sectional area for each muscle was determined by dividing muscle weight by its length and tissue density, and muscle force was compared after correction for cross-sectional area.

EMSA and reporter assays.

EMSA and supershift analyses were performed on whole muscles as previously described (49). The antibody against p65 was obtained from Rockland and antibodies against p50, c-Rel, RelB, Bcl-3, and p52 from Santa Cruz Biotechnology Inc. For reporter assays, tissue homogenates were prepared in M-PER (Pierce), and standard luciferase assays were performed.

Western blotting, kinase assays, and real-time PCR.

Muscle extracts for Western blot analysis were prepared as previously described (52) and probed using antibodies against p-p65, p-IκB, pIKK (1:500; Cell Signaling Technology), IκBα (1:500; Santa Cruz Biotechnology Inc.), IKKα (1:500; Imgenex), IKKβ (1:500; Cell Signaling Technology), IKKγ (1:500; Santa Cruz Biotechnology Inc.) and p65 (1:10,000; Rockland). IKK assays were performed according to published procedures (14, 31) with the exception that IKKγ was used to immunoprecipitate endogenous IKK. For real-time analysis, RNA was isolated from muscle tissues, and real-time PCR was performed as described previously (49) using primers listed in the Supplemental material.


All quantitative data are represented as mean ± SEM unless otherwise noted. Analysis was performed between different groups using 2-tailed Student’s t test and nonparametric Mann-Whitney U test. Statistical significance was set at P < 0.05.

Supplementary Material

Supplemental data:


We thank the members of the Guttridge laboratory, especially J. Wang, K. Ladner, and E. Hertlein, for discussions and technical advice. Special thanks go to S. Burden for MLC-Cre mice; M. Mayo for GST-p65 constructs; J. Mendell for helpful suggestions; B. McElwain for flow cytometry advice; M. Ostrowski and G. Leone for reagents; and A. Asakura for critical technical input. We also thank G. Wei, G. Lesinsky, W. Chen, T. Zabuawala, R. Opavsky, P. Trikha, J. Stein, K. Kigerl, and E. McDaniel for helpful reagents and R. Jain for critical review of the manuscript. Work was supported by NIH grants AI35098 (to A.S. Baldwin) and CA098466 (to D.C. Guttridge), and the Muscular Dystrophy Association (to D.C. Guttridge).


Nonstandard abbreviations used: CLN, centrally located nuclei; DKO, double KO; DMD, Duchenne muscular dystrophy; E-MyHC, embryonic myosin heavy chain; IKK, IκB kinase; LGMD, limb-girdle muscular dystrophy; MCP-1α, monocyte chemoattractant protein–1α; MLC, myosin light chain; NBD, NEMO-binding domain; TA, tibialis anterior.

Conflict of interest: A.S. Baldwin and S. Ghosh declare equity positions in TheraLogics Inc.

Citation for this article: J. Clin. Invest. 117:889–901 (2007). doi:10.1172/JCI30556


1. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002;82:291–329. [PubMed]
2. Emery A.E. The muscular dystrophies. Lancet. 2002;359:687–695. [PubMed]
3. Dalkilic I., Kunkel L.M. Muscular dystrophies: genes to pathogenesis. Curr. Opin. Genet. Dev. 2003;13:231–238. [PubMed]
4. Durbeej M., Campbell K.P. Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr. Opin. Genet. Dev. 2002;12:349–361. [PubMed]
5. Gorospe J.R., Tharp M.D., Hinckley J., Kornegay J.N., Hoffman E.P. A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J. Neurol. Sci. 1994;122:44–56. [PubMed]
6. Tidball J.G. Inflammatory processes in muscle injury and repair. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005;288:R345–R353. [PubMed]
7. Porreca E., et al. Haemostatic abnormalities, cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb. Haemost. 1999;81:543–546. [PubMed]
8. Porter J.D., et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum. Mol. Genet. 2002;11:263–272. [PubMed]
9. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195–2224. [PubMed]
10. Li Q., Withoff S., Verma I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol. 2005;26:318–325. [PubMed]
11. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kappaB activity. Annu. Rev. Immunol. 2000;18:621–663. [PubMed]
12. Baldwin A.S., Jr. Series introduction: the transcription factor NF-κB and human disease. J. Clin. Invest. 2001;107:3–6. [PMC free article] [PubMed]
13. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2002;2:301–310. [PubMed]
14. Cai D., et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119:285–298. [PubMed]
15. Hunter R.B., Kandarian S.C. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. . J. Clin. Invest. 2004;114:1504–1511. [PMC free article] [PubMed]
16. Baghdiguian S., et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat. Med. 1999;5:503–511. [PubMed]
17. Monici M.C., Aguennouz M., Mazzeo A., Messina C., Vita G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 2003;60:993–997. [PubMed]
18. Kumar A., Boriek A.M. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J. 2003;17:386–396. [PubMed]
19. Deconinck A.E., et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell. 1997;90:717–727. [PubMed]
20. Sasaki C.Y., Barberi T.J., Ghosh P., Longo D.L. Phosphorylation of RelA/p65 on serine 536 defines an IkappaBalpha-independent NF-kappaB pathway. J. Biol. Chem. 2005;280:34538–34547. [PubMed]
21. Carlsen H., Moskaug J.O., Fromm S.H., Blomhoff R. In vivo imaging of NF-kappa B activity. J. Immunol. 2002;168:1441–1446. [PubMed]
22. Beg A.A., Sha W.C., Bronson R.T., Ghosh S., Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167–170. [PubMed]
23. Sha W.C., Liou H.C., Tuomanen E.I., Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 1995;80:321–330. [PubMed]
24. Doi T.S., et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc. Natl. Acad. Sci. U. S. A. 1999;96:2994–2999. [PMC free article] [PubMed]
25. Spencer M.J., Marino M.W., Winckler W.M. Altered pathological progression of diaphragm and quadriceps muscle in TNF-deficient, dystrophin-deficient mice. Neuromuscul. Disord. 2000;10:612–619. [PubMed]
26. Khurana T.S., Davies K.E. Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov. 2003;2:379–390. [PubMed]
27. Charge S.B., Rudnicki M.A. Cellular and molecular regulation of muscle regeneration. Physiol. Rev. 2004;84:209–238. [PubMed]
28. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., Baldwin A.S., Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. 1999;19:5785–5799. [PMC free article] [PubMed]
29. Li Z.W., Omori S.A., Labuda T., Karin M., Rickert R.C. IKK beta is required for peripheral B cell survival and proliferation. J. Immunol. 2003;170:4630–4637. [PubMed]
30. Clausen B.E., Burkhardt C., Reith W., Renkawitz R., Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265–277. [PubMed]
31. Sakurai H., Chiba H., Miyoshi H., Sugita T., Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J. Biol. Chem. 1999;274:30353–30356. [PubMed]
32. Bothe G.W., Haspel J.A., Smith C.L., Wiener H.H., Burden S.J. Selective expression of Cre recombinase in skeletal muscle fibers. Genesis. 2000;26:165–166. [PubMed]
33. Jiang P., et al. Targeted deletion of the MLC1f/3f downstream enhancer results in precocious MLC expression and mesoderm ablation. Dev. Biol. 2002;243:281–293. [PubMed]
34. Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S., Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000;289:2363–2366. [PubMed]
35. Sherwood R.I., et al. Isolation of adult mouse myogenic progenitors: functional heterogeneity of cells within and engrafting skeletal muscle. Cell. 2004;119:543–554. [PubMed]
36. Montarras D., et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005;309:2064–2067. [PubMed]
37. May M.J., et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000;289:1550–1554. [PubMed]
38. di Meglio P., Ianaro A., Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum. 2005;52:951–958. [PubMed]
39. Lynch G.S., et al. Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. Am. J. Physiol. 1997;272:C2063–C2068. [PubMed]
40. Mourkioti F., et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Invest. 2006;116:2945–2954. [PMC free article] [PubMed]
41. Thaloor D., Miller K.J., Gephart J., Mitchell P.O., Pavlath G.K. Systemic administration of the NF-kappaB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am. J. Physiol. 1999;277:C320–C329. [PubMed]
42. Greten F.R., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118:285–296. [PubMed]
43. Li Q., et al. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc. Natl. Acad. Sci. U. S. A. 2005;102:12425–12430. [PMC free article] [PubMed]
44. Bonuccelli G., et al. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. Am. J. Pathol. 2003;163:1663–1675. [PMC free article] [PubMed]
45. Messina S., et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp. Neurol. 2006;198:234–241. [PubMed]
46. Sprong R.C., et al. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am. J. Respir. Crit. Care Med. 1998;157:1283–1293. [PubMed]
47. Jimi E., et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 2004;10:617–624. [PubMed]
48. Lavon I., et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat. Med. 2000;6:573–577. [PubMed]
49. Acharyya S., et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. 2005;8:421–432. [PubMed]
50. Straub V., Rafael J.A., Chamberlain J.S., Campbell K.P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 1997;139:375–385. [PMC free article] [PubMed]
51. Jankowski R.J., Haluszczak C., Trucco M., Huard J. Flow cytometric characterization of myogenic cell populations obtained via the preplate technique: potential for rapid isolation of muscle-derived stem cells. Hum. Gene Ther. 2001;12:619–628. [PubMed]
52. Acharyya S., et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 2004;114:370–378. [PMC free article] [PubMed]
53. Rando T.A., Blau H.M. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J. Cell Biol. 1994;125:1275–1287. [PMC free article] [PubMed]
54. Asakura A., Komaki M., Rudnicki M. Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation. 2001;68:245–253. doi: 10.1046/j.1432-0436.2001.680412.x. [PubMed] [Cross Ref]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...


  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...